Court points to 'para lifts', potential for bias in Indian Sovaldi case
This article was originally published in Scrip
Executive Summary
A recent Delhi High Court order that set aside the rejection of one of Gilead's key patent applications for its hepatitis C treatment, Sovaldi (sofosbuvir), in India has made some seemingly embarrassing observations on how the patent office may have been potentially ''influenced'' by material placed on record by pre-grant opposition applicants.